UCB SA (UCBJF)
OTHER OTC:UCBJF
Want to see UCBJF full AI Analyst Report?
UCBJF Stock Chart & Stats
$305.59
-$5.15(-2.58%)
At close: 4:00 PM EST
$305.59
-$5.15(-2.58%)
Day’s Range― - ―
52-Week Range$147.34 - $345.39
Previous CloseN/A
Volume200.00
Average Volume (3M)445.00
Market Cap
$59.59B
Enterprise Value$33.63B
Total Cash (Recent Filing)$1.76B
Total Debt (Recent Filing)$3.03B
Price to Earnings (P/E)29.1
Beta0.50
Next Earnings
Jul 23, 2026EPS Estimate
5.29Next Dividend Ex-DateN/A
Dividend Yield0.64%
Share Statistics
EPS (TTM)7.59
Shares Outstanding194,505,660
10 Day Avg. Volume881
30 Day Avg. Volume445
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue5.47
Enterprise Value/Gross Profit7.85
Enterprise Value/Ebitda16.88
Forecast
1Y Price Target
$352.55Price Target Upside15.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionAnalyst reports strong Bimzelx adoption and sales growth, particularly in United States psoriasis and hidradenitis suppurativa markets, indicating expanding revenue potential.
Label Expansion From Clinical DataHead-to-head clinical results versus a major competitor have the potential to expand Bimzelx's label and unlock a larger market opportunity across skin and joint conditions.
Underappreciated Strategic UpsideAnalyst views the company's plan to maximize Bimzelx value as underappreciated by the market, and considers current guidance conservative, implying upside if uptake outperforms expectations.
Bears Say
Foreign Exchange ExposureForeign exchange uncertainty could reduce reported revenues and amplify earnings volatility, representing a headwind for the stock's performance.
Guidance RiskConservative revenue guidance creates downside risk if product performance or market uptake falls short of what investors expect, which could pressure the stock.
UCB SA News
UCBJF FAQ
What was UCB SA’s price range in the past 12 months?
UCB SA lowest stock price was $147.34 and its highest was $345.39 in the past 12 months.
What is UCB SA’s market cap?
UCB SA’s market cap is $59.59B.
When is UCB SA’s upcoming earnings report date?
UCB SA’s upcoming earnings report date is Jul 23, 2026 which is in 94 days.
How were UCB SA’s earnings last quarter?
UCB SA released its earnings results on Feb 26, 2026. The company reported $7.595 earnings per share for the quarter, beating the consensus estimate of $6.372 by $1.223.
Is UCB SA overvalued?
According to Wall Street analysts UCB SA’s price is currently Undervalued.
Does UCB SA pay dividends?
UCB SA pays a Annually dividend of $1.583 which represents an annual dividend yield of 0.64%. See more information on UCB SA dividends here
What is UCB SA’s EPS estimate?
UCB SA’s EPS estimate is 5.29.
How many shares outstanding does UCB SA have?
UCB SA has 194,505,660 shares outstanding.
What happened to UCB SA’s price movement after its last earnings report?
UCB SA reported an EPS of $7.595 in its last earnings report, beating expectations of $6.372. Following the earnings report the stock price went down -1.485%.
Which hedge fund is a major shareholder of UCB SA?
Currently, no hedge funds are holding shares in UCBJF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
UCBJF Stock 12 Month Forecast
Average Price Target
$352.55
▲(15.37% Upside)
Technical Analysis
Ownership Overview
―
Insiders
14.58% Mutual Funds
<0.01% Other Institutional Investors
77.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---